Effettuare il login Iscriviti gratis

Adaptimmune Therapeutics Plc Short % di fluttuazione

Cos'è Short % di fluttuazione di Adaptimmune Therapeutics Plc?

Short % di fluttuazione di Adaptimmune Therapeutics Plc è 0.00%

Qual è la definizione di Short % di fluttuazione?



La percentuale breve di flottante è la quantità di azioni che vengono ridotte rispetto al float espresso in percentuale.

Short percentage of float, or short interest ratio, is calculated by taking the total amount of shares shorted and dividing it by the total amount of shares available for trade. It is an indirect metric of investor sentiment. When short percentage of float is high, above 40%, it implies company investors hope shares will decline in value. The percentage is used by both fundamental and technical traders to identify trends. The short percentage of float can also be calculated for entire exchanges to determine the sentiment of the market as a whole. If it is high of around five or greater for an exchange, this can be taken as a bearish signal, and vice versa.

Short % di fluttuazione di aziende nel Health Care settore su NASDAQ rispetto a Adaptimmune Therapeutics Plc

Cosa fa Adaptimmune Therapeutics Plc?

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.

Aziende con short % di fluttuazione simili a Adaptimmune Therapeutics Plc